Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer
Randomisierte klinische Studie zu beschleunigter präoperativer hyperfraktionierter Radiotherapie versus präoperativer hyperfraktionierter Radio-Chemotherapie bei lokal fortgeschrittenem Rektumkarzinom
British Journal of Radiology · 01.11.2024 · 97 (1163) · 1879-1889
DOI: 10.1093/bjr/tqae176 ↗Auf einen Blick
Bei resektablem Rektumkarzinom war die pathologische Komplettremission unter HART-CT häufiger als unter HART. Unterschiede bei OS und DFS waren nicht signifikant.
Fragestellung
Vergleich der pathologischen Ansprechraten nach präoperativer hyperfraktionierter Radiotherapie mit 5FU-Chemotherapie (HART-CT) versus HART bei resektablem Rektumkarzinom.
Methode
Randomisierte klinische Studie bei Patient:innen mit T2/N+ oder T3/any N; HART zweimal täglich mit 28 Fraktionen à 1.5 Gy bis 42 Gy oder HART-CT; medianes Follow-up 5.6 Jahre.
Ergebnisse
187 Patient:innen auswertbar: 95 HART, 92 HART-CT. Komplettremission: 4/95, 4 % vs. 11/92, 12 % (P = .045). OS: P = .13, HR 0.82 (95 %-KI 0.63-1.06); DFS: P = .32, HR 0.88 (95 %-KI 0.69-1.13).
Schlussfolgerung der Autor:innen
Die hyperfraktionierte präoperative Radiotherapie mit gleichzeitiger 5-Fu-basierter Chemotherapie verbesserte die pathologische Ansprechrate gegenüber HART. Die günstigeren OS- und DFS-Werte erreichten keine Signifikanz.
Kernaussagen
- Komplettremission: 4/95 unter HART vs. 11/92 unter HART-CT
- OS und DFS unterschieden sich nicht signifikant
- Spätkomplikationen waren in beiden Gruppen ähnlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Radiology, online erschienen am 06.09.2024. Verfasst von Adam Idasiak und 7 weiteren Autor:innen. Beteiligte Einrichtung: IInd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Pola…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Dose Fractionation, Radiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
The aim of this study was to compare pathological response rates after preoperative hyperfractionated radiotherapy with co-administration of chemotherapy based on 5FU (HART-CT) versus preoperative hyperfractionated radiotherapy (HART) in patients with resectable rectal cancer.
Methods
Patients with T2/N+ or T3/any N rectal cancer were randomized either to HART twice a day (28 fractions of 1.5 Gy) to total dose 42 Gy or to HART-CT. Tumour regression grade was postoperatively assessed according to the 4-point scale as recommended by the American Joint Committee on Cancer (AJCC). The secondary endpoints included overall survival (OS), disease-free survival (DFS), toxicity of preoperative treatment, locoregional, and distant failure rates. There were 187 patients eligible for analysis: 95 in HART and 92 in the HART-CT. Median follow-up was 5.6 years.
Results
The analysis demonstrated a significantly higher chance of achieving pathologic complete response in HART-CT arm: complete response was achieved in 4/95, 4% (HART) and 11/92, 12% (HART-CT) (P = .045). The differences in OS and DFS, while tending to favour HART-CT, were not significant: OS (P = .13, hazard ratio [HR] = 0.82, 95% CI, 0.63-1.06) and DFS (P = .32; HR = 0.88, 95% CI, 0.69-1.13). The locoregional failure and distant metastases rates did not statistically differ between the trial arms. The rate of late complications was similar (P = .51), grade 3+ being 8% versus 11% in the HART/HART-CT group, respectively.
Conclusions
The hyperfractionated preoperative radiotherapy with concurrent 5-Fu-based chemotherapy (HART-CT) improved pathological response rate compared to HART. This translated into favourable OS and DFS in HART-CT, but the differences did not reach the threshold for significance. Advances in knowledge A new hyperfractionated chemo-RT scheme is proposed. Histopathological major response (TRG 0-1) is associated with better clinical outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IInd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
- Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
- The Oncologic and Reconstructive Surgery Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
- Analytics and Clinical Biochemistry Department, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
ORCID-Profile: Adam Idasiak
Zitieren
APA
Idasiak, A., Ziółkowska, B., Rajczykowski, M., Galwas, K., Dębosz-Suwińska, I., Zeman, M., Mrochem-Kwarciak, J., & Suwiński, R. (2024). Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. British Journal of Radiology, 97(1163), 1879-1889. https://doi.org/10.1093/bjr/tqae176
Vancouver
Idasiak A, Ziółkowska B, Rajczykowski M, Galwas K, Dębosz-Suwińska I, Zeman M, et al. Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. British Journal of Radiology. 2024;97(1163):1879-1889. doi:10.1093/bjr/tqae176
BibTeX
@article{Idasiak2024,
author = {Idasiak, Adam and Ziółkowska, Barbara and Rajczykowski, Marcin and Galwas, Katarzyna and Dębosz-Suwińska, Iwona and Zeman, Marcin and Mrochem-Kwarciak, Jolanta and Suwiński, Rafał},
title = {Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer},
journal = {British Journal of Radiology},
year = {2024},
volume = {97},
number = {1163},
pages = {1879--1889},
doi = {10.1093/bjr/tqae176}
}
EUVIMED